Workflow
骨修复材料类植入物
icon
Search documents
春立医疗收盘下跌2.76%,滚动市盈率68.79倍,总市值87.95亿元
Jin Rong Jie· 2025-08-19 11:52
Group 1 - The core viewpoint of the article highlights that Spring Medical's stock closed at 22.93 yuan, down 2.76%, with a rolling PE ratio of 68.79 times and a total market value of 8.795 billion yuan [1] - The average PE ratio for the medical device industry is 59.49 times, with a median of 40.19 times, placing Spring Medical at the 91st position in the industry ranking [1] - As of March 31, 2025, Spring Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, PRP preparation kits, and negative pressure wound drainage kits [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - In the latest quarterly report for Q1 2025, Spring Medical achieved an operating income of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.071 million yuan, a year-on-year increase of 5.20%, with a gross profit margin of 66.69% [1]
春立医疗收盘上涨1.89%,滚动市盈率71.31倍,总市值91.17亿元
Sou Hu Cai Jing· 2025-08-15 12:28
Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 23.77 yuan, with a PE ratio of 71.31 times, significantly higher than the industry average of 56.58 times [1][2] - As of March 31, 2025, Chunzhi Medical had 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan per shareholder [1] - The company specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, and bone repair materials [1] Group 2 - In the latest quarterly report for Q1 2025, Chunzhi Medical reported revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.07 million yuan, up 5.20% year-on-year, with a gross margin of 66.69% [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, positioning Chunzhi Medical at the 92nd rank within the industry [1][2]
春立医疗收盘上涨6.39%,滚动市盈率71.97倍,总市值92.02亿元
Sou Hu Cai Jing· 2025-08-11 11:57
Core Viewpoint - Spring Medical's stock closed at 23.99 yuan, up 6.39%, with a rolling PE ratio of 71.97, marking a new low in 379 days, and a total market capitalization of 9.202 billion yuan [1] Company Summary - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, PRP preparation kits, and negative pressure wound drainage kits [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - For Q1 2025, Spring Medical reported revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.0711 million yuan, up 5.20%, with a gross profit margin of 66.69% [1] Industry Summary - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Spring Medical at the 92nd position in the industry ranking [1] - The total market capitalization of the industry averages 11.897 billion yuan, with the median at 5.767 billion yuan [2]
春立医疗收盘上涨1.75%,滚动市盈率57.51倍,总市值73.53亿元
Sou Hu Cai Jing· 2025-07-16 11:16
最新一期业绩显示,2025年一季报,公司实现营业收入2.30亿元,同比3.60%;净利润5807.11万元,同 比5.20%,销售毛利率66.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13春立医疗57.5158.832.5573.53亿行业平均 51.8747.354.50108.06亿行业中值37.4837.062.5352.67亿1九安医疗10.8510.970.85183.07亿2英科医疗 12.0913.041.08191.07亿3新华医疗14.3613.311.1792.03亿4振德医疗15.4114.530.9855.95亿5山东药玻 15.4415.491.77146.06亿6奥美医疗15.7915.481.6257.06亿7康德莱16.2616.271.3535.03亿8奥泰生物 16.8417.751.3653.69亿9九强生物16.8915.712.0783.66亿10维力医疗17.2617.942.0239.36亿11安杰思 18.0518.262.1853.58亿12安图生物19.0418.172.45217.08亿 来源:金融界 7月16日,春立医疗今日收盘19 ...
春立医疗收盘上涨1.42%,滚动市盈率55.68倍,总市值71.19亿元
Jin Rong Jie· 2025-07-11 10:42
Group 1 - The core viewpoint of the article highlights that Spring Medical has a closing price of 18.56 yuan, with a PE ratio of 55.68 times, and a total market value of 7.119 billion yuan [1] - The average PE ratio for the medical device industry is 52.06 times, with a median of 37.22 times, placing Spring Medical at the 88th position in the industry ranking [1] - As of March 31, 2025, Spring Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - In the latest quarterly report for Q1 2025, Spring Medical achieved an operating income of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.071 million yuan, a year-on-year increase of 5.20%, with a gross profit margin of 66.69% [1]
春立医疗收盘上涨1.24%,滚动市盈率56.31倍,总市值72.00亿元
Jin Rong Jie· 2025-07-07 11:19
Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 18.77 yuan, with a PE ratio of 56.31, marking a new low in 273 days, and a total market capitalization of 7.2 billion yuan [1] - The average PE ratio for the medical device industry is 51.42, with a median of 37.44, placing Chunzhi Medical at the 88th position in the industry ranking [1] - As of the first quarter of 2025, 13 institutions hold shares in Chunzhi Medical, including 8 funds, with a total holding of 31.63 million shares valued at 429 million yuan [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, with key products including spinal, trauma, joint, sports medicine implants, and surgical instruments [1] - The latest performance report for the first quarter of 2025 shows that the company achieved revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.07 million yuan, up 5.20%, with a gross profit margin of 66.69% [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1]
春立医疗收盘上涨2.66%,滚动市盈率49.71倍,总市值63.56亿元
Sou Hu Cai Jing· 2025-06-24 13:22
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Spring Medical, which closed at 16.57 yuan with a PE ratio of 49.71 times, indicating a strong market position within the orthopedic medical device industry [1][2] - Spring Medical's total market capitalization is 6.356 billion yuan, and it ranks 88th in the industry based on PE ratio, which averages 49.12 times and has a median of 36.07 times [1][2] - The company specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] Group 2 - As of March 31, 2025, Spring Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - In the first quarter of 2025, Spring Medical reported revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.071 million yuan, reflecting a year-on-year growth of 5.20% with a gross margin of 66.69% [1]
春立医疗收盘下跌2.54%,滚动市盈率49.47倍,总市值63.25亿元
Sou Hu Cai Jing· 2025-06-18 11:21
Company Overview - Spring Medical's closing price on June 18 was 16.49 yuan, down 2.54%, with a rolling PE ratio of 49.47 times and a total market capitalization of 6.325 billion yuan [1] - The company ranks 88th in the medical device industry, which has an average PE ratio of 49.10 times and a median of 36.43 times [1] - As of March 31, 2025, the number of shareholders increased to 7,167, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices [1] - The main products include spinal, trauma, joint, sports medicine implants, bone repair materials, surgical instruments, PRP preparation kits, and negative pressure wound drainage kits [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] Financial Performance - In the first quarter of 2025, Spring Medical reported revenue of 230 million yuan, a year-on-year increase of 3.60% [1] - The net profit for the same period was 58.071 million yuan, reflecting a year-on-year growth of 5.20% [1] - The sales gross margin stood at 66.69% [1]
春立医疗收盘上涨2.83%,滚动市盈率46.86倍,总市值59.91亿元
Jin Rong Jie· 2025-05-13 10:56
Group 1 - The core viewpoint of the article highlights that Chunli Medical's stock closed at 15.62 yuan, with a 2.83% increase, and a rolling PE ratio of 46.86 times, with a total market value of 5.991 billion yuan [1] - The average PE ratio for the medical device industry is 50.06 times, with a median of 36.80 times, placing Chunli Medical at the 87th position in the industry ranking [1] - As of the first quarter of 2025, 13 institutions hold shares in Chunli Medical, including 8 funds, 4 others, and 1 brokerage, with a total holding of 31.6307 million shares valued at 429 million yuan [1] Group 2 - Chunli Medical specializes in the research, production, and sales of implantable orthopedic medical devices, with main products including spinal, trauma, joint, sports medicine implants, bone repair materials, surgical instruments, PRP preparation kits, and negative pressure drainage kits [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - The latest performance report for the first quarter of 2025 shows that the company achieved an operating income of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.0711 million yuan, a year-on-year increase of 5.20%, with a gross sales margin of 66.69% [1]
春立医疗收盘下跌2.03%,滚动市盈率46.44倍,总市值59.38亿元
Sou Hu Cai Jing· 2025-05-08 11:20
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Spring Medical, indicating a decline in stock price and a relatively high PE ratio compared to industry averages [1][2] - As of May 8, Spring Medical's stock closed at 15.48 yuan, down 2.03%, with a rolling PE ratio of 46.44 times and a total market capitalization of 5.938 billion yuan [1] - The average PE ratio for the medical device industry is 49.20 times, with a median of 36.56 times, placing Spring Medical at the 87th position in the industry ranking [1][2] Group 2 - As of March 31, 2025, Spring Medical had 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - In the latest quarterly report for Q1 2025, Spring Medical achieved an operating revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.0711 million yuan, reflecting a year-on-year growth of 5.20%, with a gross profit margin of 66.69% [1]